文献速递消化道肿瘤放疗胸部肿瘤放疗

骨骼肌质量与局部晚期食管癌新辅助放化疗毒性增加相关:SAKK 75/08 亚组研究

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
PubMed 文献 · Radiat Oncol · 2019-09-11

该研究为 III 期 SAKK 75/08 研究的亚组分析,在 61 例接受三模式治疗(诱导化疗、放化疗和手术)的局部晚期食管癌患者中,于诱导化疗前、放化疗前和新辅助治疗后通过 L3 层面 CT 测量骨骼肌指数评估肌少症。采用已发表的界值,肌少症患病率从治疗前 29.5% 升至新辅助治疗期间 63.9%(p < 0.001)。肌少症患者放化疗期间 grade ≥ 3 毒性显著增加(83.3% vs 52.4%,p = 0.04),术后并发症有增加趋势但未达统计学显著(66.7% vs 42.9%,p = 0.16);在该小样本中未观察到肌少症与生存的差异。

要点

  • 新辅助治疗期间肌少症患病率从 29.5% 升至 63.9%(p < 0.001)。
  • 肌少症患者放化疗期间 grade ≥ 3 毒性显著更高(83.3% vs 52.4%,p = 0.04)。
  • 术后并发症有增加趋势但未达显著(66.7% vs 42.9%,p = 0.16)。

核心结论

  • 局部晚期食管癌三模式治疗在选择性肌少症患者中可行,新辅助放化疗增加肌少症比例,肌少症患者新辅助放化疗期间毒性风险更高,术后并发症有增加趋势但未达统计学显著。

研究设计与样本

  • III 期 SAKK 75/08 研究的亚组分析,纳入瑞士四中心 61 例接受三模式治疗(诱导化疗、放化疗和手术)的局部晚期食管癌患者。
  • 于诱导化疗前、放化疗前和新辅助治疗后通过 L3 层面横断面 CT 测量骨骼肌指数评估肌少症,采用 Martin 等已发表界值(PMID: 23530101)。

主要发现

  • 肌少症患病率从治疗前 29.5% 升至新辅助治疗期间 63.9%(p < 0.001)。
  • 肌少症与非肌少症患者的新辅助治疗和手术可行性无差异。
  • 肌少症患者放化疗期间 grade ≥ 3 毒性显著增加(83.3% vs 52.4%,p = 0.04)。
  • 肌少症患者术后并发症有增加趋势但未达统计学显著(66.7% vs 42.9%,p = 0.16)。
  • 该小样本中未观察到肌少症与生存的差异。

关键数值与推荐

  • 肌少症采用 Martin 等已发表界值(PMID: 23530101)通过 L3 骨骼肌指数判定。
  • 毒性分级采用 grade ≥ 3 标准评估放化疗期间毒性。

临床怎么用

  • 对局部晚期食管癌接受新辅助放化疗患者,可基于 L3 层面 CT 评估骨骼肌指数识别肌少症高风险人群。
  • 肌少症患者新辅助放化疗期间 grade ≥ 3 毒性风险较高,需加强毒性监测与支持治疗。

局限性

  • 亚组分析样本量小(61 例),生存分析未见差异可能受样本量限制。
  • 肌少症界值来源于既往已发表研究(Martin 等),非本研究自建。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia, the critical depletion of skeletal muscle mass, is an independent prognostic factor in several tumor entities for treatment-related toxicity and survival. In esophageal cancer, there have been conflicting results regarding the value of sarcopenia as prognostic factor, which may be attributed to the heterogeneous patient populations and the retrospective nature of previous studies. The aim of our study was therefore to determine the impact of sarcopenia on prospectively collected specific outcomes in a subgroup of patients treated within the phase III study SAKK 75/08 with trimodality therapy (induction chemotherapy, radiochemotherapy and surgery) for locally advanced esophageal cancer. METHODS: Sarcopenia was assessed by skeletal muscle index at the 3rd lumbar vertebra (L3) in cross-sectional computed tomography scans before induction chemotherapy, before radiochemotherapy and after neoadjuvant therapy in a subgroup of 61 patients from four centers in Switzerland. Sarcopenia was determined by previously established cut-off values (Martin et al., PMID: 23530101) and correlated with prospectively collected outcomes including treatment-related toxicity, postoperative morbidity, treatment feasibility and survival. RESULTS: Using the published cut-off values, the prevalence of sarcopenia increased from 29.5% before treatment to 63.9% during neoadjuvant therapy (p < 0.001). Feasibility of neoadjuvant therapy and surgery was not different in initially sarcopenic and non-sarcopenic patients. We observed in sarcopenic patients significantly increased grade ≥ 3 toxicities during chemoradiation (83.3% vs 52.4%, p = 0.04) and a non-significant trend towards increased postoperative complications (66.7% vs 42.9%, p = 0.16). No difference in survival according to sarcopenia could be observed in this small study population. CONCLUSIONS: Trimodality therapy in locally advanced esophageal cancer is feasible in selected patients with sarcopenia. Neoadjuvant chemoradiation increased the percentage of sarcopenia. Sarcopenic patients are at higher risk for increased toxicity during neoadjuvant radiochemotherapy and showed a non-significant trend to more postoperative morbidity.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Panje CM, Höng L, Hayoz S, et al. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol. 2019. PMID: 31511012. doi:10.1186/s13014-019-1372-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。